Tango Therapeutics (TNGX) Other Accumulated Expenses (2020 - 2026)

Tango Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 21.23% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 21.23% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 25.71% from the prior year.
• Other Accumulated Expenses advanced to $1.6 million in Q1 2026 per TNGX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.7 million in Q3 2024 and bottomed at $900000.0 in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $1.6 million (2023), against an average of $1.6 million.
• Across the five-year window, Other Accumulated Expenses surged 90.83% in 2024 and sank 37.04% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.3 million in 2022, then advanced by 1.58% to $1.3 million in 2023, then soared by 34.81% to $1.7 million in 2024, then dropped by 25.71% to $1.3 million in 2025, then grew by 20.87% to $1.6 million in 2026.
• Per Business Quant, the three latest TNGX Other Accumulated Expenses figures stand at $1.6 million (Q1 2026), $1.3 million (Q4 2025), and $1.7 million (Q3 2025).